RISK OF TROMBOEMBOLIC EVENTS AND ADEQUACY OF THERAPY WITH WARFARIN IN ATRIAL FIBRILLATION OF NON-VALVULAR ORIGIN
Abstract
About the Authors
A. Yu. RychkovRussian Federation
A. A. Bliznyakov
Russian Federation
N. Yu. Khorkova
Russian Federation
O. A. Nesterova
Russian Federation
References
1. Диагностика и лечение фибрилляции предсердий / Рекомендации ВНОК. - М., 2005. - 28 с.
2. Ay H., Gungor L., Arsava E.M. et al. A score to predict early risk of recurrence after ischemic stroke. // Neurology. - 2010. - Vol. 74. - № 2. - P. 128-135.
3. Choudhry N.K., Soumerai S.B., Normand S.L. et al. Warfarin prescribing in atrial fibrillation: the impact of physician, patient, and hospital characteristics. // Am J Med. - 2006. - Vol. 119. - № 7. - P. 607-615.
4. de Vos C.B., Pisters R., Nieuwlaat R. et al. Progression from Paroxysmal to Persistent Atrial Fibrillation: Clinical Correlates and Prognosis. // J Am Coll Cardiol. - 2010. -Vol. 55. - № 8. - P. 725-731.
5. DeWilde S., Carey I.M., Emmas C. et al. Trends in the prevalence of diagnosed atrial fibrillation, its treatment with anticoagulation and predictors of such treatment in UK primary care. // Heart. - 2006. - Vol. 92. - № 8. - P. 1064-1070.
6. Friberg L., Hammar N., Ringh M. et al. Stroke prophylaxis in atrial fibrillation: who gets it and who does not? Report from the Stockholm Cohort-study on Atrial Fibrillation (SCAF-study). - Eur Heart J. - 2006. - Vol. 27. - №16. - P. 1954-1964.
7. Fuster V., Ryden L.E., Cannom D.S. et al. ACC/AHA/ ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation—Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation) Developed in Collaboration With the European Heart Rhythm Association and the Heart Rhythm Society. // J Am Coll Cardiol. - 2006. - Vol. 48. - P. 854-906.
8. Gage B.F., Waterman A.D., Shannon W. et al. Validation of Clinical Classification Schemes for Predicting Stroke Results From the National Registry of Atrial Fibrillation. // JAMA. - 2001. - Vol. 285. - P. 2864-2870.
9. Hart R.G., Pearce L.A., Aguilar M.I. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. // Ann Intern Med. - 2007. - Vol. 146. - № 12. - P. 857-867.
10. Hylek E.M., Skates S.J., Sheehan M.A., Singer D.E. An Analysis of the Lowest Effective Intensity of Prophylactic Anticoagulation for Patients with Nonrheumatic Atrial Fibrillation. // 1996. - NEJM. - Vol. 335. - № 8. - P. 540-546
11. Hylek E.M., Go A.S., Chang Y. et al. Effect of Intensity of Oral Anticoagulation on Stroke Severity and Mortality in Atrial Fibrillation. // NEJM. - 2003. - Vol. 349. - № 11. - P. 1019-1026
12. Kirchhof P., Bax J., Blomstrom-Lundquist C. et al. Early and Comprehensive Management of Atrial Fibrillation: Executive Summary of the Proceedings from the 2nd AFNET-EHRA Consensus Conference ‘Research Perspectives in AF’ // European Heart Journal. - 2010. - Vol. 30. - № 24, P. 2969-2977
13. Nieuwlaat R., Capucci A., Camm A.J. et al. Atrial fibrillation management: a prospective survey in ESC member countries: the Euro Heart Survey on Atrial Fibrillation. // Eur Heart J. - 2005. - Vol. 26. - P. 2422-2434.
14. Reeves M.J., Fonarow G.C., Zhao X. et al. Quality of Care in Women With Ischemic Stroke in the GWTG Program. // Stroke. - 2009. - Vol. 40. - P.1127-1133.
15. Scott P.A., Pancioli A.M., Davis L.A. et al. Prevalence of Atrial Fibrillation and Antithrombotic Prophylaxis in Emergency Department Patients. // Stroke. - 2002. - Vol. 33. - P. 2664-2669
Review
For citations:
Rychkov A.Yu., Bliznyakov A.A., Khorkova N.Yu., Nesterova O.A. RISK OF TROMBOEMBOLIC EVENTS AND ADEQUACY OF THERAPY WITH WARFARIN IN ATRIAL FIBRILLATION OF NON-VALVULAR ORIGIN. Journal of Arrhythmology. 2010;62(62):41-44. (In Russ.)